Navigation Links
Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board

HUNTINGTON BEACH, California and AMSTERDAM, March 5 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Dr. Albert A. (Al) Luderer to its Supervisory Board.

Dr. Luderer has more than 30 years of experience in in vitro medical diagnostics, laboratory medicine and therapeutic development. Currently, he is the Chief Executive Officer and President of BioTrove, a privately held company using innovative platform technologies to dramatically increase throughput for pharmaceutical screening and genomics research, accelerating drug-discovery decisions and pipeline development. Dr. Luderer is also the Director of Light Micronics, Inc. and a Scientific Advisory Board member at Washington University's Department of Biomedical Engineering, St. Louis, MO.

"We are very pleased to welcome Al to our Supervisory Board," commented Bernhard Sixt, Ph.D., President and Chief Executive Officer of Agendia. "As we continue to expand our U.S. activities, Al's extensive experience and track record of success in the diagnostics industry will prove extremely valuable to Agendia's growth." Previously, Dr. Luderer served as Director, President and Chief Executive Officer of Light Sciences Corporation where he spearheaded the company's combined business, technical and commercial activities. Prior to joining Light Sciences Corporation, Dr. Luderer was President and Chief Operating Officer at bioMerieux, Inc., a world leader in in vitro diagnostics. From 1987 - 1993, Dr. Luderer was at Boehringer Mannheim Corporation (now Roche) where he was named Vice President of Technology Development and Support. He started his work in the sector at Corning Inc. as a key figure negotiating the joint venture diagnostic company Ciba Corning (now Siemens Healthcare Diagnostics).

Dr. Luderer holds a Bachelor of Arts from Drew University and an M.S. and Ph.D. from Rutgers University where he was a National Science Foundation pre-doctoral fellow.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

For more information please visit

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
2. Agendia Appoints VP of Business Development
3. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
4. Agendia Appoints New Chief Financial Officer
5. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
6. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
7. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
8. Agendia BV Appoints Clinical and Scientific Advisory Board
9. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
10. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
11. Agendia Joins the Personalized Medicine Coalition (PMC)
Post Your Comments:
(Date:12/1/2015)... Clara, CA (PRWEB) , ... December 01, 2015 ... ... Force Microscopy (AFM) announces Park NX10 SICM Module, an add-on scanning ion conductance ... easily integratesthe power of SICM to an AFM. , Park SICM benefits virtually ...
(Date:12/1/2015)... DIEGO , December 1, 2015 Dr. Harry Lander ... serving as Chief Science Officer and recruits ... Dr. Harry Lander , President of Regen, expands his role to ... and recruits five distinguished scientists to join ... Regen, expands his role to include serving ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells ... stages of a new closed system for isolating adipose-derived stem cells. The announcement starts ... (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction ...
(Date:11/30/2015)... Partnership includes an MPP ... the u niversity , s Solid Drug Nanoparticle (SDN) ... - up through cost cuts ... , where licensees based anywhere in the world will have the right to make, ... Africa , where licensees based anywhere in the world will have the right ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
Breaking Biology News(10 mins):